Athebio develops ultra-stable biotherapeutics using proprietary Athebody® DARPin molecules with high affinity and specificity. We partner on radiotherapeutics, T cell engagers, targeted delivery (LNP/AAV/oligo) and affinity ligands, enabling breakthrough therapeutic strategies.
Products, services, technology
Athebio’s Athebody® platform powers ultra-stable, high-affinity biotherapeutics. Our technology supports diverse applications including targeted therapies, advanced delivery systems, and affinity ligands, seamlessly integrating into partner modalities for breakthrough innovation.
Cooperation possibilities
Athebio’s Athebody® technology integrates seamlessly with partner platforms to enable transformative therapies. We actively expanding strategic partnerships in targeted therapies and affinity ligands, combining complementary expertise to enhance delivery, purification, and therapeutic impact.
- https://www.athebio.com
- +41 44 508 08 28
- Send an email
- Thomas Huber
